FDA Grants Catalyst Biosciences Orphan Drug Designation For MarzAA For The Treatment Of Factor VII Deficiency
Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Disease Designation (ODD) for its lead product candidate, subcutaneous Marzeptacog alfa
